Abstract
As a long non-coding RNA (lncRNA) and a transcriptional regulator, Metastasis associated lung adenocarcioma transcript-1 (MALAT-1) has been reported to be associated with proliferation and metastasis of hepatocellular carcinoma (HCC). However, the effects of MALAT-1 single nucleotide polymorphisms (SNPs) on HCC remains poorly understood. This study, including 624 HCC cases and 618 controls, aimed to explore the potential associations between three common tagSNPs at MALAT-1 and HCC risk in a Southern Chinese population. No significant associations were observed between the three tagSNPs and HCC risk under any genetic models after adjusting for potential confounders. Additionally, there were no any significant associations in the stratified analysis, combined effect analysis, and multifactor dimensionality reduction (MDR) analysis. Unification analysis of mediation and interaction on HCC risk further showed that four decomposition of total effects ((controlled direct effect (CDE), the reference interaction effect (INTref), the mediated interaction effect (INTmed), or the pure indirect effect (PIE)) were also not significant. Neither was the association between the MALAT-1 SNPs and progression factors of HCC, including TNM staging, metastasis, and cancer embolus; Overall, this study suggested that tagSNPs rs11227209, rs619586, and rs3200401 at MALAT-1 were not significantly associated with HCC susceptibility. Nevertheless, large population-based studies are warranted to further explore the role of MALAT-1 SNPs in HCC incidence and development.
Similar content being viewed by others
Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers having high morbidity and mortality worldwide1, especially in China2. An estimated 466,100 new HCC cases occurred in China, with an estimated 422,100 deaths in 20152. The high malignancy and rapid progress of HCC results in most patients to be diagnosed at late stage. Currently, there are no effective treatment strategies, and prognosis remains poor, with a five year survival rate lower than 15%1,3. Therefore, it is urgent to explore the pathogenesis of HCC and establish screening mechanism for high risk populations, to help prevent and detect HCC early.
The development of HCC is an extremely complicated process, which results from various environmental and genetic factors4. Epidemiological evidences have indicated that chronic infection of hepatitis B virus (HBV) and/or hepatitis C virus (HCV), alcohol drinking, and aflatoxin exposure are major risk factors for HCC5. Among genetic factors, non-coding genes, accounting for 98% of the human genome, have been found resulting in many genomic mutations related to the susceptibility of cancers6, including HCC7. However, it remains not to be fully elucidated the incidence and development of HCC.
Recently, long non-coding RNAs (lncRNAs), a novel class of non-coding RNA, have shown to play significant roles in tumorigenesis, metastasis and prognosis of cancers8. Therein, metastasis associated lung adenocarcinoma transcript-1 (MALAT-1), a kind of nuclear-retained lncRNA located on 11q369, was upregulated in multiple types of cancers, such as lung cancer10, breast cancer (BC)11, colon prostate cancer12, gastric cancer13, and HCC14,15. A prior study reported that MALAT-1 could regulate multiple gene expression through modulating transcription or alternative splicing in multiple cancers14. In liver cancer cell lines (HepG2 and Hep3B), MALAT-1 regulates cancer-related microRNAs (miRNAs), such as mir-574 and mir-20b, contributing to potential targets (such as RAS and MAPK) and Wnt/β-catenin signaling pathway, thus promoting HCC development16. Moreover, MALAT-1 was a proto-oncogene for HCC, which can activate and induce the oncogenic splicing factor SRSF1 through the Wnt pathway17. Additionally, lncRNA MALAT-1 can also serve as a cancer biomarker18,19 owing to its ability to facilitate cell proliferation and migration20. Although emerging reports have described the function of MALAT-1 in cancers, knowledge gaps remain regrading the mechanism for cancer pathogenesis.
Single nucleotide polymorphisms (SNPs), which can alter the expression and function of gene, were used to predict disease risks and clinical prognosis21. Recently, an increasing number of studies have also explored associations between SNPs at lncRNA MALAT-1 and cancers risks. For example, the rs3200401 at MALAT-1 was not associated with BC risk22, while the rs619586 variant yielded a lower BC22, with no association for lung cancer23 and HCC7. These results conferred to these SNPs were inconsistent between different cancer types. Additionally, association studies between MALAT-1 SNPs and HCC were relatively limited. Therefore, we selected three tagSNPs (rs11227209, rs619586 and rs3200401) at MALAT-1, and conducted a hospital-based case-control study to systematically explore the association between MALAT-1 SNPs and development of HCC in the Southern Chinese population.
Results
Subjects’ characteristics
Characteristics of 624 HCC cases and 618 controls are presented in Supplementary Table 2. As described previously24, the distributions of age and gender were similar in both groups (P = 0.429 and 0.752, respectively). HBV infection status was the strongest associated risk factor for HCC (adjusted OR = 15.92, 95% CI = 11.74–21.59). Additionally, alcohol consumption, smoking, ditch water drinking, and family history of cancers were also significantly associated with increased risk of HCC (all P < 0.05). Therefore, being regarded as potential confounders, these risk factors were adjusted in the following genetic analyses, as well as age and gender.
Association between MALAT-1 SNPs and HCC risk
The genotype distributions of three SNPs in controls were all in agreement with Hardy-Weinberg equilibrium (P = 0.671, 0.399, and 0.825 for rs11227209, rs619586, and rs3200401, respectively). Table 1 showed the distributions of genotypes and alleles and their associations with HCC risk. However, no significant associations were observed between all three MALAT-1 SNPs and HCC susceptibility under any genetic models. Under the dominant model, the adjusted ORs for rs11227209, rs619586, and rs3200401 were 1.29 (95% CI = 0.83–2.03), 1.17 (95% CI = 0.80–1.72) and 0.95 (95% CI = 0.69–1.31), respectively. Combined effect of risk alleles at MALAT-1 on HCC was also analyzed, however, no significant association was observed (Table 2).
Stratified analysis of genetic association with HCC risk
We further performed stratified analysis for genetic associations by environmental factors (Supplementary Fig. 1). No significant association between MALAT-1 rs11227209, rs619586, rs3200401 and HCC susceptibility was found in all subgroups.
Pair-wise and high-order interactions on HCC risk
No significant interaction was observed between genetic, environmental factors and HCC risk under multiplicative and additive interactions models.
Additionally, high-order interaction analysis were conducted using MDR analysis. However, no evidence of high-order gene-environment interactions on HCC risk were found (Supplementary Table 3 and Fig. 2). The best interaction model was still one-factor model, including HBV.
Unification analysis of mediation and interaction on HCC risk
Four-way decomposition of total effects (TE) were shown in Table 3. Neither the controlled direct effect (CDE), the reference interaction effect (INTref), the mediated interaction effect (INTmed), nor the pure indirect effect (PIE) was significantly in the association between MALAT-1 tagSNPs and HCC risk. Additionally, neither significant overall interaction effects between HBV status and tagSNPs, nor significant overall mediated effects role of HBV status was shown. Furthermore, there were no direct or indirect association effects of SNPs on HCC risk. And the total association effects were also not statistically significant.
Associations between the SNPs and clinicopathological characteristics of HCC
Association analysis between three MALAT-1 SNPs and TNM stage, metastasis, and cancer embolus were performed (Table 4). Rs11227209, rs619586, and rs3200401 were not significantly associated with metastasis of HCC (adjusted OR = 0.72, 95% CI = 0.35–1.48 for rs11227209, adjusted OR = 0.75, 95% CI = 0.41–1.39 for rs619586, and adjusted OR = 1.08, 95% CI = 0.66–1.77 for rs3200401), cancer embolus of HCC (adjusted OR = 0.60, 95% CI = 0.23–1.58 for rs11227209, adjusted OR = 0.65, 95% CI = 0.28–1.49 for rs619586, adjusted OR = 1.55, 95% CI = 0.87–2.78 for rs3200401), and TNM stage of HCC (adjusted OR = 1.07, 95% CI = 0.55–2.08 for rs11227209, adjusted OR = 0.97, 95% CI = 0.55–1.71 for rs619586 and adjusted OR = 0.96, 95% CI = 0.59–1.56 for rs3200401).
Discussion
Previous studies have demonstrated the roles of lncRNAs as potential oncogenes and critical regulators of tumorigenesis25,26. MALAT-1, a highly conserved lncRNA in mammals27, was proposed to be a potential molecular biomarker of multiple cancers to screen and diagnosis high-risk cancer populations28. The highest plasma level of MALAT-1 was found in HCC patients, followed by other hepatic disease, than in healthy controls, indicating the link of MALAT-1 over-expression to liver damage29. MALAT-1 expression in HCC tissues was also significantly higher than that in paired non-tumor liver tissues (P < 0.01)16,30. Furthermore, MALAT-1 was upregulated in human liver cancer cell lines compared to normal hepatic cell line (P < 0.010), as shown in the gene expression omnibus (GEO) database16. The above biological evidences together suggested that MALTA-1 is an promising susceptibility gene for HCC31. However, it is still unknown whether the common variants of MALTA-1 affect the incidence and development of HCC.
The present study investigated whether tagSNPs of MALAT-1, including rs11227209, rs619586, and rs3200401 exhibited effects on the development of HCC. However, no associated evidence between MALAT-1 tagSNPs and HCC risk were found. Furthermore, there were no statistically significant associations in the combined effects analysis and stratified analysis. The multiplicative and additive interactions and high-order interactions between genes and environments were further explored, but were not significantly associated.
There has been evidence showing that MALAT-1 rs619586 AG/GG could confer a protective effect on BC in Han Chinese Beijing (CHB) population22. However, no associated effect was found for lung cancer in CHS population23. Additionally, the association between MALAT-1 rs619586 and HBV-related HCC risk also did not reach statistical significance in 1300 HBV-positive HCC patients and 1344 HBV persistent carriers (P = 0.057)7. In this study of CHS population, we further conducted subgroup analysis by HBV status and found that there were still no significant association between rs619586 and HCC risk neither in HBV-positive subgroups nor in HBV-negative subjects. The differences between these association results may be due to dissimilarities in the genetic background of participants and the tissue-specific effect of lncRNA19. Peng et al. found MALAT-1 rs3200401 did not significantly associated with BC risk in 487 BC patients and 489 cancer-free controls (P = 0.056)22. To our knowledge, the effect of rs11227209/rs3200401 on HCC risk was not previously explored. The present study first explored the associations in southern Chinese population, but did not find significant associations between rs11227209/rs3200401 and HCC risk.
Prior studies also reported that MALAT-1 could promote proliferation, invasion, and metastasis of HCC cells32,33, and is an independent prognostic factor for HCC recurrence after liver transplantation34. This study further explored the associations between rs11227209, rs619586 and clinic characteristics of HCC, including TNM staging, metastasis, and cancer embolus. The results showed that three tagSNPs were not significantly associated with clinicopathological characteristics of HCC30. Nevertheless, additional studies are needed to better understand the mechanism.
The systematic and comprehensive statistical strategy, designing of tagSNP which can capture all common SNPs at MALAT-1 was adopted in this study. However, limitations still remained. Firstly, potential selection bias may exist because of hospital-based case-control study. Though over 600 cases and 600 controls were included in present study, statistical power was still not enough for subgroup analysis and interaction analysis. Additionally, although many potential epidemiological factors were adjusted for in this study, some unmeasured factors including diabetes should be evaluated in future studies. Moreover, CHS was used as the reference population, which may influence population specificity. Last, it is possible that true HCC-related common SNPs at MALAT-1 may not be included in the catalog of variants, or MALAT-1 low frequency variants potentially having stronger effects on HCC risk have not been explored.
In conclusion, this case-control study suggest that three tagSNPs rs11227209, rs619586, and rs3200401 at MALAT-1 were not associated with HCC risk in this Southern Chinese population. More comprehensive and systematic design (large, population-based, and diverse ethnic population) studies are needed to explore the true MALAT-1 pathogenic variants on HCC risk.
Methods
The present study was approved by the Ethics Committee of Guangdong Pharmaceutical University, it was performed in accordance with the approved guidelines of the Declaration of Helsinki. All research and experiments were performed in accordance with relevant guidelines and regulations. Informed consent agreement was obtained from each participant or their legal representatives.
Study samples
This hospital-based case-control study included 624 HCC patients and 618 cancer-free controls. All participants were consecutively recruited from Shunde hospital of Southern Medical University, in Guangdong, China from September 2010 to October 2014. HCC patients were clinically and histologically diagnosed by pathological examination combined with imaging examination (computed tomography or magnetic resonance imaging). Patients with other cancers were excluded in this study, such as cholangiocarcinoma. Controls were frequency matched with cases based on age (±5 years) and gender, and randomly selected from physical examination populations without history of cancers in the same hospital at the same time when HCC patients were enrolled. Serological markers including HBsAg, anti-HBs, anti-HBc, and anti-HCV were collected from medical records. The information of clinical characteristics of HCC cases, including TNM stage, metastasis status, and cancer embolus, were also reviewed from medical records.
Interviewers were trained to collect epidemiological information, such as gender, age (age at diagnosis for cases), drinking status, smoking status, history of ditch water drinking, and family history of cancer among first-degree relatives. Detail definitions were described previously24,35. Additionally, 5 ml whole blood was gathered from each participant following in-person interviews.
TagSNPs selection and genotyping
To capture all common SNPs across the whole MALAT-1 gene, we used the design strategy of tagSNPs. There were totally five common SNPs (minor allele frequency (MAF) > 5%) at MALAT-1. Among them, rs619586, rs65660 and rs664589 were in the same LD block. Rs11227209 and rs3200401 were the proxies for themselves. Finally, three MALAT-1 tagSNPs (rs619586, rs11227209 and rs3200401) among the Han Chinese South (CHS) population, were screened out with Haploview version 4.2 software (Cambridge, MA, USA), with the r2 > 0.8 and MAF ≥ 5%.
Genomic DNA was extracted from 5 ml whole blood by TIANamp Genomic DNA Kit (Tiangen, Beijing, China) according to the manufacturer. Three tagSNPs were genotyped by TaqMan real-time polymerase chain reaction (PCR) Assay. Primers were designed by AssayDesigner software V3.1. Additional details on PCR primers and probes were previously described24. In order to maintain genotyping quality, knowledge of participants’ disease status were blind and 5% random samples were selected to repeat genotyping, with the concordance rate of 100%. The recall rates were 99.84%, 99.84%, and 99.75% for rs11227209, rs619586 and r3200401, respectively (Supplementary Table 1).
Statistical analyses
Hardy-Weinberg equilibrium (HWE) for genotypes were examined using a goodness-of-fit chi-square test in controls. The differences in frequency distribution of demographic characteristics and genotypes between cases and controls were assessed using student’s t-test (for continuous variables), Person chi-square test or Fisher’s exact probability (for categorical variables). Associations between three SNPs and HCC risk were estimated by odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs) in unconditional logistic regression models. All plausible genetic models, including dominant, recessive, and additive models for these three SNPs, were also assessed. Finally, dominant model was chosen in the following stratified analysis, combined analysis, and interaction analysis. Furthermore, multiplicative and additive gene-environment interactions were estimated using multiplicative term in logistic regression models36. We further used unification analysis of mediation and interaction37,38 to explore the effect of MALAT-1 tagSNPs on HCC risk due to mediation and/or interaction with HBV status. Multifactor dimensionality reduction (MDR) analysis was also used to explore potential high-order gene-environment interactions, using MDR V3.0.2 software39. Additionally, associations between SNPs and clinicopathological characteristics in HCC patients were also evaluated. A two-tailed P < 0.05 was applied as the criterion for statistical significance. Statistical analyses were conducted by software SAS9.4 (SAS Institute, Inc., Cary, NC, USA).
References
Torre, L. A. et al. Global cancer statistics, 2012. Ca A Cancer Journal for Clinicians 65, 87–108 (2015).
Chen, W. Q. et al. Cancer statistics in China, 2015. Ca A Cancer Journal for Clinicians 66, 115–132 (2016).
Wang, P., Ouyang, L., Zheng, L. & Wang, Z. Identifying hepatocellular carcinoma-related genes and pathways by system biology analysis. Irish Journal of Medical Science 184, 357–364 (2015).
Hirokawa, F. et al. Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma. Surgical Oncology 25, 24–29 (2016).
Song, P. et al. Screening for and surveillance of high-risk patients with HBV-related chronic liver disease: promoting the early detection of hepatocellular carcinoma in China. Bioscience Trends 7, 1–6 (2013).
Huarte, M. The emerging role of lncRNAs in cancer. Nature Medicine 21, 1253–1261 (2015).
Liu, Y. et al. A Genetic Variant in Long Non-Coding RNA HULC Contributes to Risk of HBV-Related Hepatocellular Carcinoma in a Chinese Population. Plos One 7, e35145 (2012).
Gupta, S. C. & Tripathi, Y. N. Potential of long non‐coding RNAs in cancer patients: From biomarkers to therapeutic targets. International Journal of Cancer 140, 1955–1967 (2017).
Tripathi, V. et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Molecular Cell 39, 925–938 (2010).
Lopezayllon, B. D. et al. Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations. Cancer Medicine 3, 1099–111 (2015).
Zhao, Z., Chen, C., Liu, Y. & Wu, C. 17β-Estradiol treatment inhibits breast cell proliferation, migration and invasion by decreasing MALAT-1 RNA level. Biochemical & Biophysical Research Communications 445, 388–393 (2014).
Zheng, H. T. et al. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. International Journal of Clinical & Experimental Pathology 7, 3174–3181 (2014).
Okugawa, Y. et al. Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. Carcinogenesis 35, 2731–2739 (2014).
Yoshimoto, R., Mayeda, A., Yoshida, M. & Nakagawa, S. MALAT1 long non-coding RNA in cancer. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1859, 192–199 (2016).
Ren, D. et al. Novel insight into MALAT-1 in cancer: Therapeutic targets and clinical applications. Oncology Letters 11, 1621–1630 (2016).
Shin, W. C. et al. Identification of aberrant overexpression of long non-coding RNA MALAT1 and role as a regulatory microRNA in liver cancer. Molecular & Cellular Toxicology 13, 443–451 (2017).
Malakar, P. et al. Long Noncoding RNA MALAT1 Promotes Hepatocellular Carcinoma Development by SRSF1 Upregulation and mTOR Activation. Cancer Research 77, 1155–1167 (2017).
Tian, X. & Xu, G. Clinical value of lncRNA MALAT1 as a prognostic marker in human cancer: systematic review and meta-analysis. Bmj Open 5, e008653 (2015).
Guerrieri, F. Long non-coding RNAs era in liver cancer. World Journal of Hepatology 7, 1971–1973 (2015).
Hou, Z. et al. The long non-coding RNA MALAT1 promotes the migration and invasion of hepatocellular carcinoma by sponging miR-204 and releasing SIRT1. Tumour Biol 39 (2017).
Tripathi, V. et al. Long Noncoding RNA MALAT1 Controls Cell Cycle Progression by Regulating the Expression of Oncogenic Transcription Factor B-MYB. Plos Genetics 9, e1003368 (2013).
Peng, R. et al. Association analyses of genetic variants in long non-coding RNA MALAT1 with breast cancer susceptibility and mRNA expression of MALAT1 in Chinese Han population. Gene 642, 241–248 (2018).
Gong, W. J. et al. Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Tumor Biology 37, 8349–8358 (2016).
Li, L. et al. A potentially functional variant of ARID1B interacts with physical activity in association with risk of hepatocellular carcinoma. Oncotarget 8, 31057–31064 (2017).
Yarmishyn, A. A. & Kurochkin, I. V. Long noncoding RNAs: a potential novel class of cancer biomarkers. Frontiers in Genetics 6, 145 (2015).
Shi, T., Gao, G. & Cao, Y. Long Noncoding RNAs as Novel Biomarkers Have a Promising Future in Cancer Diagnostics. Disease Markers, 9085195 (2016).
Ji, P. et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22, 8031–8034 (2003).
Wang, Y. et al. The Long Noncoding RNA MALAT-1 is A Novel Biomarker in Various Cancers: A Meta-analysis Based on the GEO Database and Literature. Journal of Cancer 7, 991–1001 (2016).
Konishi, H. et al. Plasma level of metastasis‐associated lung adenocarcinoma transcript 1 is associated with liver damage and predicts development of hepatocellular carcinoma. Cancer Science 107, 149–154 (2016).
Huang, Z. et al. Sp1 cooperates with Sp3 to upregulate MALAT1 expression in human hepatocellular carcinoma. Oncology Reports 34, 2403–2412 (2015).
Li, Z., Dou, P., Liu, T. & He, S. Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets. Cellular Physiology\s&\sbiochemistry:international. Journal of Experimental Cellular Physiology, Biochemistry,\s&\spharmacology 42, 1407–1419 (2017).
Hou, Z. et al. HBx-related long non-coding RNA MALAT1 promotes cell metastasis via up-regulating LTBP3 in hepatocellular carcinoma. American Journal of Cancer Research 7, 845–856 (2017).
Liu, D. et al. Knockdown of long non-coding RNA MALAT1 inhibits growth and motility of human hepatoma cells via modulation of miR-195. Journal of Cellular Biochemistry 119, 1368–1380 (2018).
Lai, M. et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Medical Oncology 29, 1810–1816 (2012).
Chen, J. H. et al. Effects of interactions between environmental factors and KIF1B genetic variants on the risk of hepatocellular carcinoma in a Chinese cohort. World J Gastroenterol 22, 4183–4190 (2016).
Wu, H. & Wu, L. Identification of significant host factors for HIV dynamics modelled by non-linear mixed-effects models. Statistics in Medicine 21, 753–771 (2010).
Barney, N. et al. Open-source multifactor dimensionality reduction (MDR) software for detecting and interpreting gene-gene interactions. Meeting of the International-Genetic-Epidemiology-Society; (2005).
Vanderweele, T. J. A unification of mediation and interaction: a 4-way decomposition. Epidemiology 25, 749–761 (2014).
Valeri, L. & Vanderweele, T. J. Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. Psychol Methods 18, 137–150 (2013).
Acknowledgements
This work was supported by the National Natural Science Foundations of China (Grant No. 71573059), Natural Science Foundation of Guangdong Province, China (Grant No. 2016A030313809), the Training Programme for Outstanding Young Teachers in Higher Education Institutions of Guangdong Province (Grant No. YQ2015098).
Author information
Authors and Affiliations
Contributions
Conception and design: X.J., J.Z., L.L. and Y.G.; Development of methodology: X.J., J.Z. and Y.G.; Acquisition of data: X.J., J.Z., Z.L., N.T., X.L., L.P., S.C. and X.Y.; Analysis and interpretation of data: X.J., J.Z. and Y.G.; Writing, review and/or revision of the manuscript: X.J., J.Z., L.L. and Y.G.; Administrative, technical, or material support: Z.L. and Y.G. All authors reviewed and approved the final manuscript.
Corresponding authors
Ethics declarations
Competing Interests
The authors declare no competing interests.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
41598_2019_47165_MOESM1_ESM.pdf
Association of tagSNPs at lncRNA MALAT-1 with HCC Susceptibility in a Southern Chinese Population (SREP-18-42781A)_clean version
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Ji, X., Zhang, J., Liu, L. et al. Association of tagSNPs at lncRNA MALAT-1 with HCC Susceptibility in a Southern Chinese Population. Sci Rep 9, 10895 (2019). https://doi.org/10.1038/s41598-019-47165-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-019-47165-w
This article is cited by
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.